Healthcare / Medical DevicesTechnical Analysis Guide

ABT Stock Analysis

Abbott Laboratories

💡 Quick Answer

Across 4 APEX technical signals, ABT is currently split between bullish and bearish readings — 0 bullish, 0 bearish as of 2026-07-08. Run a live analysis to see the current composite score.

ABT is a high-quality compounder with moderate ATR (1.5-2.5%). Ideal for position traders seeking healthcare exposure without biotech binary risk.

RSI Behavior: Steady 40-65 rangeCGM Growth Catalyst: FreeStyle Libre market shareMoving Average: 200-day key support

Abbott is a diversified healthcare company spanning medical devices, diagnostics, nutrition, and branded generics. Its FreeStyle Libre continuous glucose monitor is the world's most widely used CGM and the primary growth engine. The diagnostics segment became critical during COVID-19 and has since stabilized, while the medical devices segment (cardiac rhythm, electrophysiology) provides durable recurring revenue.

LIVE CHART·ABT. DailyPowered by TradingView

Open ABT on TradingView ↗Affiliate link

Get live ABT signal analysis

APEX runs 8 signals on ABT in real time: RSI, MACD, Fibonacci, Volume, and more.

Analyze ABT Now →

Why Do Traders Watch ABT?

ABT is a high-quality compounder with moderate ATR (1.5-2.5%). Ideal for position traders seeking healthcare exposure without biotech binary risk. It is sensitive to FreeStyle Libre market share data and U.S. CGM reimbursement policy. Post-earnings moves of 3-6% are typical. The stock tends to outperform during defensive rotations and underperform in aggressive risk-on environments.

Is ABT a Buy Right Now? Current Signal Readings

📊RSI BehaviorSteady 40-65 range

ABT's RSI oscillates in a tight range relative to most healthcare stocks. RSI dips to 40-45 in uptrends mark reliable accumulation zones where institutional buyers step in to defend the stock ahead of FreeStyle Libre sales data releases.

📊CGM Growth CatalystFreeStyle Libre market share

Each quarterly disclosure of FreeStyle Libre global sales and new geography launches moves ABT 2-4% independently of other metrics. The CGM market is expected to double by 2028. Any acceleration in adoption or new product approval (Libre 3+) is the highest-conviction ABT catalyst.

📊Moving Average200-day key support

ABT's 200-day moving average has acted as durable support in every major correction since 2016. When ABT approaches the 200-day with RSI below 45 and declining volume, institutional accumulation typically begins within 1-2 sessions.

📊Dividend Growth50+ year dividend raiser

Abbott is a Dividend King with 50+ consecutive years of dividend increases. This creates a floor of income-oriented institutional demand at elevated yield levels, providing asymmetric downside protection that pure growth stocks lack.

📋 ABT Key Stats for Traders

⚡ATR (14-day)1.5-2.5% of price

📦Avg daily volume~5-8 million shares

🎯Key metricFreeStyle Libre sales growth

📅Post-earnings move3-6% typical

🔗 Related Stocks

TMO MDT DXCM BSX

Run a live ABT analysis

APEX combines RSI, MACD, Fibonacci, Volume, and 4 more signals into one composite score in under 30 seconds.

Analyze ABT Free →

Advanced charting for ABT on TradingView ↗

💬 Frequently Asked Questions. ABT

QIs ABT a good stock to buy right now?

AWhether ABT is a buy depends on its current technical positioning. ABT is a high-quality compounder with moderate ATR (1.5-2.5%). Ideal for position traders seeking healthcare exposure without biotech binary risk. It is sensitive to FreeStyle Libre market share data and U.S. CGM reimbursement policy. Post-earnings moves of 3-6% are typical. The stock tends to outperform during defensive rotations and underperform in aggressive risk-on environments. Run a live APEX analysis at apexstockintel.com to see the current composite score, RSI, and MACD signals. Updated every trading day.

QWhat are the most important technical signals for ABT?

AThe four key signals for ABT are: RSI Behavior (Steady 40-65 range). ABT's RSI oscillates in a tight range relative to most healthcare stocks. RSI dips to 40-45 in uptrends mark reliable accumulation zones where institutional buyers step in to defend the stock ahead of FreeStyle Libre sales data releases.. CGM Growth Catalyst (FreeStyle Libre market share). Each quarterly disclosure of FreeStyle Libre global sales and new geography launches moves ABT 2-4% independently of other metrics. The CGM market is expected to double by 2028. Any acceleration in adoption or new product approval (Libre 3+) is the highest-conviction ABT catalyst.. Moving Average (200-day key support). ABT's 200-day moving average has acted as durable support in every major correction since 2016. When ABT approaches the 200-day with RSI below 45 and declining volume, institutional accumulation typically begins within 1-2 sessions.. Dividend Growth (50+ year dividend raiser). Abbott is a Dividend King with 50+ consecutive years of dividend increases. This creates a floor of income-oriented institutional demand at elevated yield levels, providing asymmetric downside protection that pure growth stocks lack.

QWhat is ABT's RSI telling traders right now?

AABT's RSI oscillates in a tight range relative to most healthcare stocks. RSI dips to 40-45 in uptrends mark reliable accumulation zones where institutional buyers step in to defend the stock ahead of FreeStyle Libre sales data releases. APEX scores ABT's RSI as part of its 8-factor composite signal. Updated daily.

QHow does ABT behave technically compared to other Healthcare / Medical Devices stocks?

AABT is in the Healthcare / Medical Devices sector. Abbott is a diversified healthcare company spanning medical devices, diagnostics, nutrition, and branded generics. Its FreeStyle Libre continuous glucose monitor is the world's most widely used CGM and the primary growth engine. The diagnostics segment became critical during COVID-19 and has since stabilized, while the medical devices segment (cardiac rhythm, electrophysiology) provides durable recurring revenue. Key stats: ATR (14-day): 1.5-2.5% of price, Avg daily volume: ~5-8 million shares, Key metric: FreeStyle Libre sales growth, Post-earnings move: 3-6% typical.

QWhat MACD signals work best for ABT?

AMACD measures momentum direction via the relationship between two exponential moving averages. Bullish crossovers (MACD line crossing above the signal line) indicate increasing upward momentum, while bearish crossovers signal the opposite. APEX tracks ABT's MACD histogram direction daily.

OTHER STOCK GUIDES

Technology49

+−